Raptor Pharmaceutical Corp (RPTP)

9.00
0.00 (0.00)
NASDAQ : Health Care
Prev Close 9.00
Open 8.95
Day Low/High 8.95 / 9.05
52 Wk Low/High 2.94 / 14.90
Volume 753.41K
Avg Volume 2.45M
Exchange NASDAQ
Shares Outstanding 85.31M
Market Cap 767.76M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)
29 Drugs Facing FDA Approval in 2012

29 Drugs Facing FDA Approval in 2012

An updated calendar listing FDA drug approval decisions and advisory panels for the remainder of 2012.

5 Stocks Under $10 Set to Trigger Big Moves

5 Stocks Under $10 Set to Trigger Big Moves

These under-$10 stocks look poised to trade higher from current levels.

Playing for Pennies

There really are no themes working at the moment.

Biotech Has Momentum

Takeover news has the sector buzzing this morning.

Can't Shake Off the Continent

Eurozone worries weigh down better-than-expected U.S. jobs data.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look poised to break out and trade higher from current prices.

Raptor Orphan Drug Study Succeeds

Raptor Orphan Drug Study Succeeds

Raptor's RP103 designed to be more convenient for patients with ultra-rare genetic disorder.

A Poor Opening

A Poor Opening

Early dip-buyers get slapped down, and the S&P approaches last week's lows.

A Poor Opening

Early dip-buyers get slapped down, and the S&P approaches last week's lows.

5 Heavily Shorted Market Leaders Set to Soar

5 Heavily Shorted Market Leaders Set to Soar

These market-leading stocks could see massive short squeezes on any positive catalyst.

More Hot Biotech Trades for Second Half 2011

More Hot Biotech Trades for Second Half 2011

These looming FDA drug approvals and clinical trial results are pivotal events in the lifeline of a biotech company.

Raptor Pharmaceutical Hires Patrick Reichenberger To Lead Commercial Development Of DR Cysteamine For Nephropathic Cystinosis

Raptor Pharmaceutical Hires Patrick Reichenberger To Lead Commercial Development Of DR Cysteamine For Nephropathic Cystinosis

Contracts in Place for Cambrex Corporation and Patheon, Inc. to Manufacture Active Pharmaceutical Ingredient and Commercial Product, Respectively

Raptor Pharmaceutical Commences Phase 2 Clinical Trial Of DR Cysteamine For The Potential Treatment Of Huntington's Disease

Raptor Pharmaceutical Commences Phase 2 Clinical Trial Of DR Cysteamine For The Potential Treatment Of Huntington's Disease

Raptor Announces Grant Award and NeuroTrans(TM) IP Update

Biotech Stock Mailbag Readers' Portfolio: Update

Biotech Stock Mailbag Readers' Portfolio: Update

The BSMRP, a portfolio of biotech and drug stocks chosen by readers of my weekly Mailbag, is down 23% this year.

10 Firms Expecting Clinical Trial Results

Here's a list of drug and biotech firms with impending clinical trials results.

Raptor Pharmaceutical Announces License Agreement For Convivia(TM)

Raptor Pharmaceutical Announces License Agreement For Convivia(TM)

Uni Pharma to Market Convivia(TM) in Taiwan

Raptor Pharmaceutical Enrolls First Patient In Pivotal Phase 3 Study Of DR Cysteamine For The Potential Treatment Of Cystinosis

Raptor Pharmaceutical Enrolls First Patient In Pivotal Phase 3 Study Of DR Cysteamine For The Potential Treatment Of Cystinosis

Randomized, Crossover Study to Evaluate DR Cysteamine as a Lower-Dose, More Tolerable Alternative to Immediate-Release Cysteamine

Popular, Jackson Hewitt: Midday Volume Plays

Several stocks trading near $5 were moving on above-average volume during Monday's session.

Interstate Hotels, Neuralstem: Midday Volume Plays

Several stocks trading near $5 were moving on above-average volume during Friday's session.

Raptor's Genetic Disorder Drug Meets Study Goals

Raptor's Genetic Disorder Drug Meets Study Goals

Raptor Pharmaceutical's genetic disorder drug meets midstage study goals